The Food and Drugs Authority (FDA) has disclosed that some health facilities across the country are administering unregistered Oxytocin Injection 10iu/ml.
According to the FDA, these pharmaceutical products are not registered and therefore, their quality safety and efficacy cannot be ascertained.
In a statement issued on Friday, 21 April 2023, the FDA said the unregistered brands are Beltocin by Belco Pharma PVT Ltd, Oxytocin by Entrance Pharmaceuticals, Oxytocin by AMROS Pharma, Oxytocin Anhui Hongye Pharmaceutical Company Ltd and Oxytocin Jackson Laboratories PVT Ltd.
Others are Gold Vision by Anhui Hongye Pharmaceutical Company Ltd, Derm by Shandong Shenglu Pharmaceutical Company Ltd, A-tocin by Health Care Pharma, Extocin by Anhui Hongye Pharmaceutical Company Ltd and Pitons manufactured by Shanxi Shuguang Pharm. Company Ltd.
Oxytocin Injection is a medication administered to begin or improve labour and is also used to reduce bleeding after childbirth.
The FDA, therefore, informed all health facilities and medical stores in the possession of these products to “stop using them immediately and return them to the nearest FDA offices throughout the country.”
The authority also assured the public that they are collaborating with importers to ensure that the market is rid of these unregistered pharmaceutical products.